ArticleJournal of pharmacy & bioallied sciences2019
Cost of Illness Study of Patients with Dengue Hemorrhagic Fever at One of the Private Hospitals in Yogyakarta.
Article in Journal of pharmacy & bioallied sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- The economic burden of dengue: a systematic literature review of unit costs for non-fatal episodes treated in the formal healthcare system.BMC infectious diseases · 2026Pooled it
- Early intervention of 5% albumin shown superior control of vascular integrity and function compared to ringer's lactatein hospitalized adult with grade I & II Dengue hemorrhagic fever: a multicenter randomized controlled trial in Indonesia.Tropical diseases, travel medicine and vaccines · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue hemorrhagic fever (DHF) caused by the dengue virus is one of the high-prevalence diseases in tropical countries, such as Indonesia. It has been highlighted that high-prevalence diseases are strongly correlated with high-treatment costs. In particular, Yogyakarta has been reported as one of the provinces with a high prevalence of DHF. This study aimed to estimate the cost of illness because of DHF and to analyze the correlation between the use of drugs with its cost and length of stay, with total hospital administrative cost at one of the private hospitals in Yogyakarta. A cross-sectional study was applied in this study by collecting patients' medical record and financial data, such as demographic characteristic, medication, length of stay, and direct medical cost health-care perspective. The numbers of dengue patients were applied in this study by considering 87 patients and 143 patients with DHF in 2015 and 2016, respectively. Indirect medical costs were collected from a questionnaire by 20 respondents. Spearman's statistical test was used in this study to conduct the bivariate test. The average direct medical cost from the perspective of health care in 2015 and 2016 in DHF patients with Badan Penyelenggara Jaminan Sosial (BPJS) insurance and non-BPJS insurance was US$243.6; US$363.41 and US$368.13; US$427.03. The indirect medical costs showed that the highest percentage productivity loss was US$70.98-212.95. Correlation between the numbers of drug with drug cost was significant (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.